PMC:7205724 / 18927-19106
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
652 | 106-114 | Species | denotes | patients | Tax:9606 |
656 | 48-66 | Chemical | denotes | methylprednisolone | MESH:D008775 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T143 | 79-93 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T165 | 48-66 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
LitCovid-sample-MedDRA
Id | Subject | Object | Predicate | Lexical cue | meddra_id |
---|---|---|---|---|---|
T18 | 79-93 | http://purl.bioontology.org/ontology/MEDDRA/10022891 | denotes | immunoglobulin | http://purl.bioontology.org/ontology/MEDDRA/10021496 |
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T106 | 48-66 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T151 | 0-179 | Sentence | denotes | After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
656 | 48-66 | Chemical | denotes | methylprednisolone | MESH:D008775 |
652 | 106-114 | Species | denotes | patients | Tax:9606 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T32422 | 0-5 | IN | denotes | After |
T38661 | 6-15 | VBG | denotes | switching |
T47400 | 16-18 | TO | denotes | to |
T27854 | 19-22 | DT | denotes | the |
T88178 | 23-29 | JJ | denotes | double |
T22917 | 30-34 | NN | denotes | dose |
T27562 | 35-37 | IN | denotes | of |
T69861 | 38-47 | NN | denotes | 1600 mg/d |
T26688 | 48-66 | NN | denotes | methylprednisolone |
T91618 | 67-71 | CC | denotes | plus |
T63033 | 72-78 | NN | denotes | 20 g/d |
T82872 | 79-93 | NN | denotes | immunoglobulin |
T48110 | 93-94 | -COMMA- | denotes | , |
T64285 | 95-98 | DT | denotes | all |
T67888 | 99-101 | IN | denotes | of |
T16788 | 102-105 | DT | denotes | the |
T67776 | 106-114 | NNS | denotes | patients |
T6163 | 115-123 | VBN | denotes | improved |
T27596 | 124-126 | IN | denotes | in |
T10929 | 127-130 | DT | denotes | the |
T87507 | 131-139 | JJ | denotes | clinical |
T10805 | 139-140 | -COMMA- | denotes | , |
T49266 | 141-151 | NN | denotes | laboratory |
T95692 | 151-152 | -COMMA- | denotes | , |
T51590 | 153-156 | CC | denotes | and |
T63732 | 157-169 | JJ | denotes | paraclinical |
T58895 | 170-178 | NNS | denotes | outcomes |
R26413 | T6163 | T32422 | arg1Of | improved,After |
R62745 | T38661 | T32422 | arg2Of | switching,After |
R35046 | T64285 | T38661 | arg1Of | all,switching |
R97543 | T38661 | T47400 | arg1Of | switching,to |
R45642 | T22917 | T47400 | arg2Of | dose,to |
R79576 | T22917 | T27854 | arg1Of | dose,the |
R56085 | T22917 | T88178 | arg1Of | dose,double |
R64025 | T22917 | T27562 | arg1Of | dose,of |
R36622 | T91618 | T27562 | arg2Of | plus,of |
R47040 | T26688 | T69861 | arg1Of | methylprednisolone,1600 mg/d |
R96957 | T26688 | T91618 | arg1Of | methylprednisolone,plus |
R59825 | T82872 | T91618 | arg2Of | immunoglobulin,plus |
R2563 | T82872 | T63033 | arg1Of | immunoglobulin,20 g/d |
R17542 | T6163 | T48110 | arg1Of | improved,"," |
R33163 | T64285 | T67888 | arg1Of | all,of |
R47106 | T67776 | T67888 | arg2Of | patients,of |
R68832 | T67776 | T16788 | arg1Of | patients,the |
R41521 | T64285 | T6163 | arg1Of | all,improved |
R92060 | T6163 | T27596 | arg1Of | improved,in |
R79224 | T58895 | T27596 | arg2Of | outcomes,in |
R14909 | T58895 | T10929 | arg1Of | outcomes,the |
R43963 | T58895 | T87507 | arg1Of | outcomes,clinical |
R46705 | T87507 | T10805 | arg1Of | clinical,"," |
R31644 | T49266 | T10805 | arg2Of | laboratory,"," |
R53992 | T58895 | T49266 | arg1Of | outcomes,laboratory |
R52803 | T51590 | T95692 | arg1Of | and,"," |
R16749 | T10805 | T51590 | arg1Of | ",",and |
R63324 | T63732 | T51590 | arg2Of | paraclinical,and |
R41915 | T58895 | T63732 | arg1Of | outcomes,paraclinical |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T143 | 79-93 | Body_part | denotes | immunoglobulin | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T151 | 0-179 | Sentence | denotes | After switching to the double dose of 1600 mg/d methylprednisolone plus 20 g/d immunoglobulin, all of the patients improved in the clinical, laboratory, and paraclinical outcomes. |